Last reviewed · How we verify

Ovidrel (CHORIOGONADOTROPIN ALFA)

Merck KGaA · FDA-approved approved Recombinant protein Quality 36/100

At a glance

Generic nameCHORIOGONADOTROPIN ALFA
SponsorMerck KGaA
Drug classGonadotropin
TargetLutropin-choriogonadotropic hormone receptor
ModalityRecombinant protein
Therapeutic areaImmunology
PhaseFDA-approved
First approval2000

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: